Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure
Congestive heart failure is a relatively common clinical problem 1 that is associated with the progressive impairment of left ventricular function and a poor long-term prognosis 2 . Angiotensin-converting-enzyme inhibitors have been shown to improve survival among patients with heart failure 3 , 4 ;...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1993-07, Vol.329 (3), p.149-155 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 155 |
|---|---|
| container_issue | 3 |
| container_start_page | 149 |
| container_title | The New England journal of medicine |
| container_volume | 329 |
| creator | Feldman, Arthur M Bristow, Michael R Parmley, William W Carson, Peter E Pepine, Carl J Gilbert, Edward M Strobeck, John E Hendrix, Grady H Powers, Eric R Bain, Raymond P White, B.G |
| description | Congestive heart failure is a relatively common clinical problem
1
that is associated with the progressive impairment of left ventricular function and a poor long-term prognosis
2
. Angiotensin-converting-enzyme inhibitors have been shown to improve survival among patients with heart failure
3
,
4
; however, the role of positive inotropic agents is less clear
5
. Two major classes of oral inotropic agents have been clinically evaluated: agents that increase the intracellular concentration of cyclic AMP by stimulating the beta-adrenergic receptor or inhibiting phosphodiesterase, and drugs that increase the intracellular sodium concentration
6
. Oral agents that increase intracellular levels of cyclic AMP have not . . . |
| doi_str_mv | 10.1056/NEJM199307153290301 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223982646</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>5599028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-150cbb2d5f8e659e0b39028237368f6cf769e6c3c679c8f3ee792767f0892ed83</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWKu_wEtQb7Kar83HUaS1Sqs9qNclm00wpZutyRbpvzelxZM6l5kXnvedYQA4x-gGo5LfPo-eZlgpigQuKVGIInwABnmmBWOIH4IBQkQWTCh6DE5SWqBcmKkBmI-cs6ZPsHPw3aagow9dsLALcNbF2je-30Admq3q9XKrfIBz3XsbsuvL9x9wYnXs4Vj75TraU3Dk9DLZs30fgrfx6PV-UkxfHh7v76aFYUz1BS6RqWvSlE5aXiqLaqryiYQKyqXjxgmuLDfUcKGMdNRaoYjgwiGpiG0kHYKLXe4qdp9rm_pq0a1jyCsrQqiShDOeocu_IKwk5RwpzjJFd5SJXUrRumoVfavjpsKo2v63-uW_2XW1z9bJ6KWLOhiffqxMkhwuMna9w9o2VcEu2n9DvwF7foRx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983660964</pqid></control><display><type>article</type><title>Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Feldman, Arthur M ; Bristow, Michael R ; Parmley, William W ; Carson, Peter E ; Pepine, Carl J ; Gilbert, Edward M ; Strobeck, John E ; Hendrix, Grady H ; Powers, Eric R ; Bain, Raymond P ; White, B.G</creator><creatorcontrib>Feldman, Arthur M ; Bristow, Michael R ; Parmley, William W ; Carson, Peter E ; Pepine, Carl J ; Gilbert, Edward M ; Strobeck, John E ; Hendrix, Grady H ; Powers, Eric R ; Bain, Raymond P ; White, B.G</creatorcontrib><description>Congestive heart failure is a relatively common clinical problem
1
that is associated with the progressive impairment of left ventricular function and a poor long-term prognosis
2
. Angiotensin-converting-enzyme inhibitors have been shown to improve survival among patients with heart failure
3
,
4
; however, the role of positive inotropic agents is less clear
5
. Two major classes of oral inotropic agents have been clinically evaluated: agents that increase the intracellular concentration of cyclic AMP by stimulating the beta-adrenergic receptor or inhibiting phosphodiesterase, and drugs that increase the intracellular sodium concentration
6
. Oral agents that increase intracellular levels of cyclic AMP have not . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199307153290301</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Angiotensin-converting enzyme inhibitors ; Biological and medical sciences ; Cardiac glycosides ; Cardiotonic agents ; Cardiovascular system ; Congestive heart failure ; Digoxin ; Drug therapy ; Failure analysis ; Glycosides ; Heart attacks ; Heart failure ; Heart rate ; Long-term effects ; Lupus ; Medical sciences ; Morbidity ; Mortality ; Neutropenia ; Patients ; Peptidyl-dipeptidase A ; Pharmacology. Drug treatments ; Potassium ; Quality of life ; Sodium ; Studies ; Vesnarinone</subject><ispartof>The New England journal of medicine, 1993-07, Vol.329 (3), p.149-155</ispartof><rights>Copyright © 1993 Massachusetts Medical Society. All rights reserved.</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-150cbb2d5f8e659e0b39028237368f6cf769e6c3c679c8f3ee792767f0892ed83</citedby><cites>FETCH-LOGICAL-c449t-150cbb2d5f8e659e0b39028237368f6cf769e6c3c679c8f3ee792767f0892ed83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199307153290301$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199307153290301$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4820967$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Feldman, Arthur M</creatorcontrib><creatorcontrib>Bristow, Michael R</creatorcontrib><creatorcontrib>Parmley, William W</creatorcontrib><creatorcontrib>Carson, Peter E</creatorcontrib><creatorcontrib>Pepine, Carl J</creatorcontrib><creatorcontrib>Gilbert, Edward M</creatorcontrib><creatorcontrib>Strobeck, John E</creatorcontrib><creatorcontrib>Hendrix, Grady H</creatorcontrib><creatorcontrib>Powers, Eric R</creatorcontrib><creatorcontrib>Bain, Raymond P</creatorcontrib><creatorcontrib>White, B.G</creatorcontrib><title>Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure</title><title>The New England journal of medicine</title><description>Congestive heart failure is a relatively common clinical problem
1
that is associated with the progressive impairment of left ventricular function and a poor long-term prognosis
2
. Angiotensin-converting-enzyme inhibitors have been shown to improve survival among patients with heart failure
3
,
4
; however, the role of positive inotropic agents is less clear
5
. Two major classes of oral inotropic agents have been clinically evaluated: agents that increase the intracellular concentration of cyclic AMP by stimulating the beta-adrenergic receptor or inhibiting phosphodiesterase, and drugs that increase the intracellular sodium concentration
6
. Oral agents that increase intracellular levels of cyclic AMP have not . . .</description><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Biological and medical sciences</subject><subject>Cardiac glycosides</subject><subject>Cardiotonic agents</subject><subject>Cardiovascular system</subject><subject>Congestive heart failure</subject><subject>Digoxin</subject><subject>Drug therapy</subject><subject>Failure analysis</subject><subject>Glycosides</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart rate</subject><subject>Long-term effects</subject><subject>Lupus</subject><subject>Medical sciences</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Peptidyl-dipeptidase A</subject><subject>Pharmacology. Drug treatments</subject><subject>Potassium</subject><subject>Quality of life</subject><subject>Sodium</subject><subject>Studies</subject><subject>Vesnarinone</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kE1LAzEQhoMoWKu_wEtQb7Kar83HUaS1Sqs9qNclm00wpZutyRbpvzelxZM6l5kXnvedYQA4x-gGo5LfPo-eZlgpigQuKVGIInwABnmmBWOIH4IBQkQWTCh6DE5SWqBcmKkBmI-cs6ZPsHPw3aagow9dsLALcNbF2je-30Admq3q9XKrfIBz3XsbsuvL9x9wYnXs4Vj75TraU3Dk9DLZs30fgrfx6PV-UkxfHh7v76aFYUz1BS6RqWvSlE5aXiqLaqryiYQKyqXjxgmuLDfUcKGMdNRaoYjgwiGpiG0kHYKLXe4qdp9rm_pq0a1jyCsrQqiShDOeocu_IKwk5RwpzjJFd5SJXUrRumoVfavjpsKo2v63-uW_2XW1z9bJ6KWLOhiffqxMkhwuMna9w9o2VcEu2n9DvwF7foRx</recordid><startdate>19930715</startdate><enddate>19930715</enddate><creator>Feldman, Arthur M</creator><creator>Bristow, Michael R</creator><creator>Parmley, William W</creator><creator>Carson, Peter E</creator><creator>Pepine, Carl J</creator><creator>Gilbert, Edward M</creator><creator>Strobeck, John E</creator><creator>Hendrix, Grady H</creator><creator>Powers, Eric R</creator><creator>Bain, Raymond P</creator><creator>White, B.G</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>19930715</creationdate><title>Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure</title><author>Feldman, Arthur M ; Bristow, Michael R ; Parmley, William W ; Carson, Peter E ; Pepine, Carl J ; Gilbert, Edward M ; Strobeck, John E ; Hendrix, Grady H ; Powers, Eric R ; Bain, Raymond P ; White, B.G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-150cbb2d5f8e659e0b39028237368f6cf769e6c3c679c8f3ee792767f0892ed83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Biological and medical sciences</topic><topic>Cardiac glycosides</topic><topic>Cardiotonic agents</topic><topic>Cardiovascular system</topic><topic>Congestive heart failure</topic><topic>Digoxin</topic><topic>Drug therapy</topic><topic>Failure analysis</topic><topic>Glycosides</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart rate</topic><topic>Long-term effects</topic><topic>Lupus</topic><topic>Medical sciences</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Peptidyl-dipeptidase A</topic><topic>Pharmacology. Drug treatments</topic><topic>Potassium</topic><topic>Quality of life</topic><topic>Sodium</topic><topic>Studies</topic><topic>Vesnarinone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feldman, Arthur M</creatorcontrib><creatorcontrib>Bristow, Michael R</creatorcontrib><creatorcontrib>Parmley, William W</creatorcontrib><creatorcontrib>Carson, Peter E</creatorcontrib><creatorcontrib>Pepine, Carl J</creatorcontrib><creatorcontrib>Gilbert, Edward M</creatorcontrib><creatorcontrib>Strobeck, John E</creatorcontrib><creatorcontrib>Hendrix, Grady H</creatorcontrib><creatorcontrib>Powers, Eric R</creatorcontrib><creatorcontrib>Bain, Raymond P</creatorcontrib><creatorcontrib>White, B.G</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feldman, Arthur M</au><au>Bristow, Michael R</au><au>Parmley, William W</au><au>Carson, Peter E</au><au>Pepine, Carl J</au><au>Gilbert, Edward M</au><au>Strobeck, John E</au><au>Hendrix, Grady H</au><au>Powers, Eric R</au><au>Bain, Raymond P</au><au>White, B.G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure</atitle><jtitle>The New England journal of medicine</jtitle><date>1993-07-15</date><risdate>1993</risdate><volume>329</volume><issue>3</issue><spage>149</spage><epage>155</epage><pages>149-155</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Congestive heart failure is a relatively common clinical problem
1
that is associated with the progressive impairment of left ventricular function and a poor long-term prognosis
2
. Angiotensin-converting-enzyme inhibitors have been shown to improve survival among patients with heart failure
3
,
4
; however, the role of positive inotropic agents is less clear
5
. Two major classes of oral inotropic agents have been clinically evaluated: agents that increase the intracellular concentration of cyclic AMP by stimulating the beta-adrenergic receptor or inhibiting phosphodiesterase, and drugs that increase the intracellular sodium concentration
6
. Oral agents that increase intracellular levels of cyclic AMP have not . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJM199307153290301</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1993-07, Vol.329 (3), p.149-155 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_223982646 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Angiotensin-converting enzyme inhibitors Biological and medical sciences Cardiac glycosides Cardiotonic agents Cardiovascular system Congestive heart failure Digoxin Drug therapy Failure analysis Glycosides Heart attacks Heart failure Heart rate Long-term effects Lupus Medical sciences Morbidity Mortality Neutropenia Patients Peptidyl-dipeptidase A Pharmacology. Drug treatments Potassium Quality of life Sodium Studies Vesnarinone |
| title | Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A34%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Vesnarinone%20on%20Morbidity%20and%20Mortality%20in%20Patients%20with%20Heart%20Failure&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Feldman,%20Arthur%20M&rft.date=1993-07-15&rft.volume=329&rft.issue=3&rft.spage=149&rft.epage=155&rft.pages=149-155&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199307153290301&rft_dat=%3Cproquest_cross%3E5599028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983660964&rft_id=info:pmid/&rfr_iscdi=true |